Index S&P 500
P/E -
EPS (ttm) -8.72
Insider Own 11.44%
Shs Outstand 387.00M
Perf Week -5.30%
Market Cap 10.02B
Forward P/E -
EPS next Y -7.47
Insider Trans 0.43%
Shs Float 342.49M
Perf Month -7.47%
Income -3357.00M
PEG -
EPS next Q -2.96
Inst Own 72.20%
Short Float 19.23%
Perf Quarter -20.18%
Sales 3.18B
P/S 3.15
EPS this Y -8.51%
Inst Trans 1.56%
Short Ratio 6.13
Perf Half Y -38.10%
Book/sh 26.01
P/B 1.00
EPS next Y 25.85%
ROA -22.81%
Short Interest 65.86M
Perf Year -81.22%
Cash/sh 15.45
P/C 1.68
EPS next 5Y 20.72%
ROE -29.34%
52W Range 23.15 - 138.07
Perf YTD -37.71%
Dividend Est. -
P/FCF -
EPS past 5Y -42.94%
ROIC -31.18%
52W High -81.24%
Beta 1.86
Dividend TTM -
Quick Ratio 4.14
Sales past 5Y 121.86%
Gross Margin 48.06%
52W Low 11.88%
ATR (14) 1.33
Dividend Ex-Date -
Current Ratio 4.22
EPS Y/Y TTM 44.29%
Oper. Margin -117.37%
RSI (14) 46.10
Volatility 1.96% 2.60%
Employees 5800
Debt/Eq 0.07
Sales Y/Y TTM -38.25%
Profit Margin -105.67%
Recom 2.86
Target Price 43.85
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 18.22%
Payout -
Rel Volume 1.28
Prev Close 25.40
Sales Surprise 1.71%
EPS Surprise 19.13%
Sales Q/Q -35.33%
Earnings May 01 BMO
Avg Volume 10.74M
Price 25.90
SMA20 -3.26%
SMA50 -1.53%
SMA200 -35.71%
Trades
Volume 13,737,830
Change 1.97%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-13-25 Initiated
Citigroup
Neutral
$40
Feb-18-25 Downgrade
Barclays
Overweight → Equal Weight
$111 → $45
Jan-29-25 Downgrade
Goldman
Buy → Neutral
$99 → $51
Dec-18-24 Downgrade
Argus
Buy → Hold
Dec-10-24 Resumed
BofA Securities
Underperform
$41
Nov-19-24 Initiated
Berenberg
Hold
$42
Nov-18-24 Upgrade
HSBC Securities
Hold → Buy
$58
Nov-15-24 Initiated
Wolfe Research
Underperform
$40
Oct-17-24 Initiated
Bernstein
Mkt Perform
$55
Sep-13-24 Downgrade
Oppenheimer
Outperform → Perform
Sep-13-24 Downgrade
JP Morgan
Neutral → Underweight
$88 → $70
Sep-13-24 Downgrade
Jefferies
Buy → Hold
$120 → $65
Aug-28-24 Upgrade
HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade
Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade
HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade
Oppenheimer
Perform → Outperform
$142
Nov-29-23 Initiated
Canaccord Genuity
Hold
$82
Nov-03-23 Upgrade
HSBC Securities
Reduce → Hold
$89 → $69
Nov-02-23 Downgrade
Deutsche Bank
Hold → Sell
$125 → $60
Show Previous Ratings
Jun-20-25 05:50PM
Jun-16-25 05:09PM
11:20AM
Jun-13-25 05:50PM
12:15PM
08:42AM
08:14AM
(Pharmaceutical Technology)
07:37AM
12:39AM
Jun-12-25 07:25PM
11:19AM
08:15AM
04:25AM
Jun-11-25 10:20AM
10:20AM
07:00AM
Jun-10-25 04:10PM
(Investor's Business Daily)
10:19AM
10:10AM
09:46AM
08:18AM
Jun-09-25 07:12PM
06:09PM
(Investor's Business Daily)
Jun-06-25 05:06PM
04:16PM
04:08PM
11:31AM
Jun-05-25 11:30AM
Jun-04-25 11:30AM
04:15AM
Jun-03-25 12:16PM
09:23AM
07:59AM
(The Wall Street Journal)
Jun-02-25 09:00PM
(The Wall Street Journal)
04:41PM
02:35PM
01:30PM
12:09PM
11:39AM
10:38AM
09:49AM
09:46AM
(The Wall Street Journal)
09:46AM
09:43AM
08:37AM
08:35AM
06:29AM
May-31-25 01:05PM
(Associated Press Finance)
09:30AM
12:16AM
May-30-25 10:00AM
May-29-25 05:06PM
01:08PM
01:07PM
01:01PM
(Pharmaceutical Technology)
11:08AM
11:01AM
09:06AM
07:45AM
07:36AM
May-28-25 11:43PM
08:01PM
(Associated Press Finance)
06:06PM
May-27-25 07:00AM
May-26-25 11:35AM
11:01AM
09:41AM
06:30AM
May-23-25 07:53PM
04:19PM
04:19PM
04:05PM
May-22-25 12:35PM
10:48AM
07:15AM
May-21-25 08:31PM
08:15PM
04:58PM
11:57AM
(Pharmaceutical Technology)
11:43AM
(Investor's Business Daily)
11:43AM
(Investor's Business Daily)
11:10AM
10:30AM
08:37AM
07:51AM
07:00AM
May-20-25 11:52PM
05:44PM
05:06PM
03:55PM
03:21PM
01:54PM
01:45PM
01:12PM
12:22PM
(Investor's Business Daily)
11:56AM
May-19-25 10:27PM
05:18PM
09:42AM
May-16-25 04:35PM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hussain Abbas Director Jun 11 '25 Sale 28.00 312 8,736 580 Jun 12 04:22 PM Hussain Abbas Director Jun 11 '25 Proposed Sale 28.00 312 8,736 Jun 11 10:06 AM Bancel Stephane Chief Executive Officer Mar 03 '25 Buy 31.22 160,314 5,004,318 9,210,686 Mar 04 04:27 PM SAGAN PAUL Director Mar 03 '25 Buy 31.76 31,620 1,004,251 312,027 Mar 04 04:24 PM Klinger Shannon Thyme Chief Legal Officer Dec 09 '24 Sale 44.68 529 23,637 20,446 Dec 10 04:08 PM Klinger Shannon Thyme Officer Dec 09 '24 Proposed Sale 44.68 529 23,637 Dec 09 03:18 PM Klinger Shannon Thyme Chief Legal Officer Dec 03 '24 Sale 43.30 112 4,849 19,837 Dec 04 05:11 PM Hoge Stephen President Dec 03 '24 Sale 43.30 314 13,595 1,443,904 Dec 04 05:08 PM Klinger Shannon Thyme Officer Dec 03 '24 Proposed Sale 43.30 112 4,849 Dec 03 04:11 PM Hoge Stephen Officer Dec 03 '24 Proposed Sale 43.30 314 13,595 Dec 03 03:23 PM Mock James M Chief Financial Officer Nov 29 '24 Sale 42.79 1,420 60,761 11,066 Dec 02 04:26 PM Klinger Shannon Thyme Chief Legal Officer Nov 29 '24 Sale 42.79 1,418 60,675 19,717 Dec 02 04:19 PM Hoge Stephen President Nov 29 '24 Sale 42.79 291 12,452 1,443,567 Dec 02 04:15 PM Hoge Stephen Officer Nov 29 '24 Proposed Sale 42.79 291 12,452 Nov 29 03:54 PM Klinger Shannon Thyme Officer Nov 29 '24 Proposed Sale 42.79 1,418 60,675 Nov 29 03:49 PM Mock James M Officer Nov 29 '24 Proposed Sale 42.79 1,420 60,761 Nov 29 03:35 PM Hoge Stephen President Nov 11 '24 Sale 46.10 277 12,771 1,443,248 Nov 12 04:14 PM Hoge Stephen Officer Nov 11 '24 Proposed Sale 46.10 277 12,771 Nov 12 09:27 AM Mock James M Chief Financial Officer Oct 07 '24 Sale 60.12 715 42,986 9,505 Oct 08 04:19 PM Klinger Shannon Thyme Chief Legal Officer Sep 09 '24 Sale 73.57 551 40,539 18,154 Sep 10 04:15 PM Klinger Shannon Thyme Officer Sep 09 '24 Proposed Sale 73.57 551 40,539 Sep 09 03:29 PM Klinger Shannon Thyme Chief Legal Officer Sep 03 '24 Sale 76.99 114 8,777 17,566 Sep 04 05:42 PM Hoge Stephen President Sep 03 '24 Sale 76.99 318 24,483 1,443,002 Sep 04 04:26 PM Klinger Shannon Thyme Officer Sep 03 '24 Proposed Sale 76.99 114 8,777 Sep 03 03:58 PM Hoge Stephen Officer Sep 03 '24 Proposed Sale 76.99 318 24,482 Sep 03 03:42 PM Mock James M Chief Financial Officer Aug 29 '24 Sale 78.03 162 12,640 8,767 Aug 30 04:37 PM Klinger Shannon Thyme Chief Legal Officer Aug 29 '24 Sale 78.03 162 12,640 17,447 Aug 30 04:34 PM Hoge Stephen President Aug 29 '24 Sale 78.03 300 23,408 1,442,668 Aug 30 04:32 PM Mock James M Chief Financial Officer Aug 28 '24 Sale 79.39 1,321 104,881 8,600 Aug 29 04:45 PM Klinger Shannon Thyme Chief Legal Officer Aug 28 '24 Sale 79.39 1,319 104,722 17,280 Aug 29 04:03 PM Klinger Shannon Thyme Officer Aug 29 '24 Proposed Sale 78.03 162 12,640 Aug 29 03:52 PM Mock James M Officer Aug 29 '24 Proposed Sale 78.03 162 12,640 Aug 29 03:43 PM Hoge Stephen Officer Aug 29 '24 Proposed Sale 78.03 300 23,408 Aug 29 03:38 PM Mock James M Officer Aug 28 '24 Proposed Sale 79.39 1,321 104,881 Aug 28 04:47 PM Klinger Shannon Thyme Officer Aug 28 '24 Proposed Sale 79.39 1,319 104,722 Aug 28 04:30 PM Hoge Stephen President Aug 12 '24 Sale 84.10 254 21,363 1,442,357 Aug 13 04:33 PM Hoge Stephen Officer Aug 12 '24 Proposed Sale 84.10 254 21,363 Aug 12 04:05 PM AFEYAN NOUBAR Director Jul 31 '24 Sale 119.96 15,000 1,799,443 2,224,015 Aug 02 07:00 PM NOUBAR B AFEYAN Director Jul 31 '24 Proposed Sale 118.84 15,000 1,782,600 Jul 31 04:18 PM AFEYAN NOUBAR Director Jul 24 '24 Sale 117.80 15,000 1,766,972 2,239,015 Jul 26 07:00 PM AFEYAN NOUBAR Director Jul 17 '24 Sale 122.84 15,000 1,842,651 2,254,015 Jul 19 07:00 PM Hoge Stephen President Jul 15 '24 Sale 121.12 15,000 1,816,800 1,442,089 Jul 16 04:08 PM AFEYAN NOUBAR Director Jul 10 '24 Sale 117.08 15,000 1,756,177 2,269,015 Jul 12 07:00 PM Mock James M Chief Financial Officer Jul 08 '24 Sale 118.24 689 81,465 7,269 Jul 09 04:34 PM AFEYAN NOUBAR Director Jun 26 '24 Sale 127.22 15,000 1,908,293 2,284,015 Jun 28 07:00 PM